Augmentin, a combination of amoxicillin and clavulanate potassium, effectively targets a broad range of bacterial infections. Amoxicillin tackles susceptible bacteria, while clavulanate inhibits beta-lactamases, enzymes that often render amoxicillin ineffective. This combination extends Augmentin’s reach to bacteria resistant to amoxicillin alone.
Specifically, Augmentin shows potent activity against Gram-positive bacteria including Streptococcus pneumoniae (a common cause of pneumonia and ear infections), Staphylococcus aureus (though resistance is increasing; check local antibiograms), and Streptococcus pyogenes (strep throat). Gram-negative bacteria such as Haemophilus influenzae (often involved in respiratory infections) and Moraxella catarrhalis (contributing to ear and respiratory infections) are also susceptible.
Anaerobic bacteria, frequently implicated in intra-abdominal and pelvic infections, like Bacteroides fragilis, also respond to Augmentin’s action, though certain strains may show resistance. Always consult local antibiograms for current resistance patterns in your area.
However, Augmentin’s spectrum doesn’t encompass all bacteria. Pseudomonas aeruginosa, a common hospital-acquired pathogen, typically resists Augmentin. Similarly, enterobacteriaceae like Escherichia coli and Klebsiella pneumoniae demonstrate varying levels of resistance; local susceptibility data is paramount for appropriate prescribing.
Remember, proper diagnosis and susceptibility testing are key to successful treatment. Augmentin’s effectiveness depends on the specific bacteria causing the infection and its susceptibility to the drug.
